Cargando…
Therapeutic Potential of BAY-117082, a Selective NLRP3 Inflammasome Inhibitor, on Metastatic Evolution in Human Oral Squamous Cell Carcinoma (OSCC)
SIMPLE SUMMARY: Each year, new cases of oral cancer occur and metastasis represents the primary determinant for survival. Thus, there is a need to improve the preoperative assessment of metastatic risk. Scientific evidence discovered that BAY 11-7082, a powerful inhibitor of the NLRP3 inflammasome,...
Autores principales: | Casili, Giovanna, Scuderi, Sarah Adriana, Lanza, Marika, Filippone, Alessia, Mannino, Deborah, Giuffrida, Raffaella, Colarossi, Cristina, Mare, Marzia, Capra, Anna Paola, De Gaetano, Federica, Portelli, Marco, Militi, Angela, Cuzzocrea, Salvatore, Paterniti, Irene, Esposito, Emanuela |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10216277/ https://www.ncbi.nlm.nih.gov/pubmed/37345134 http://dx.doi.org/10.3390/cancers15102796 |
Ejemplares similares
-
NLRP3 Inflammasome Inhibitor BAY-117082 Reduces Oral Squamous Cell Carcinoma Progression
por: Scuderi, Sarah Adriana, et al.
Publicado: (2021) -
Poly (ADP-Ribose) Polymerase Inhibitor, ABT888, Improved Cisplatin Effect in Human Oral Cell Carcinoma
por: Paterniti, Irene, et al.
Publicado: (2021) -
Modulation of NLRP3 Inflammasome Attenuated Inflammatory Response Associated to Diarrhea-Predominant Irritable Bowel Syndrome
por: Scuderi, Sarah Adriana, et al.
Publicado: (2020) -
Protein Kinase Inhibitors as a New Target for Immune System Modulation and Brain Cancer Management
por: Filippone, Alessia, et al.
Publicado: (2022) -
Immunomodulatory Effect of Microglia-Released Cytokines in Gliomas
por: Lanza, Marika, et al.
Publicado: (2021)